LISINOPRIL AND HYDROCHLOROTHIAZIDE

Post-LOE

lisinopril and hydrochlorothiazide tablets

Gen Pharmaceuticals

ANDAORALTABLET

Approved

Jul 2002

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

LISINOPRIL AND HYDROCHLOROTHIAZIDE (lisinopril and hydrochlorothiazide tablets) by Gen Pharmaceuticals is mechanism of action lisinopril inhibits angiotensin-converting enzyme (ace) in human subjects and animals. Approved for hypertension, to lower blood pressure. First approved in 2002.

Drug data last refreshed 1w ago

Mechanism of Action

Mechanism of Action Lisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the…

Pharmacologic Class:

Thiazide Diuretic

Indications (2)

Worked on LISINOPRIL AND HYDROCHLOROTHIAZIDE at Gen Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.